Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Immucor faces FTC (Federal Trade Commission) probe over acquisitions

This article was originally published in Clinica

Executive Summary

Blood screening specialist Immucor has come under the scrutiny of the US Federal Trade Commission (FTC) in a non-public investigation over a possible breach of federal antitrust laws. The FTC sent Immucor a letter, received on October 12, requesting certain documents and information connected to three acquisitions made from 1996 to 1999. These were a $4.5m purchase of monoclonal antibody-based reagent maker Dominion Biologicals (Halifax, Nova Scotia); a $25m deal for blood serology reagents specialist Gamma Biologicals (Houston, Texas); and the acquisition of the immunohaematology business belonging to Ventura, California-based Biopool International for approximately $8.5m in cash and mixed notes.

Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT050097

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel